Yin Yue, Feng Weibo, Chen Jie, Chen Xilang, Wang Guodong, Wang Shuai, Xu Xiao, Nie Yongzhan, Fan Daiming, Wu Kaichun, Xia Limin
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, 710032, Shaanxi Province, China.
Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
Exp Hematol Oncol. 2024 Aug 1;13(1):72. doi: 10.1186/s40164-024-00539-x.
Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy with high incidence, recurrence, and metastasis rates. The emergence of immunotherapy has improved the treatment of advanced HCC, but problems such as drug resistance and immune-related adverse events still exist in clinical practice. The immunosuppressive tumor microenvironment (TME) of HCC restricts the efficacy of immunotherapy and is essential for HCC progression and metastasis. Therefore, it is necessary to elucidate the mechanisms behind immunosuppressive TME to develop and apply immunotherapy. This review systematically summarizes the pathogenesis of HCC, the formation of the highly heterogeneous TME, and the mechanisms by which the immunosuppressive TME accelerates HCC progression and metastasis. We also review the status of HCC immunotherapy and further discuss the existing challenges and potential therapeutic strategies targeting immunosuppressive TME. We hope to inspire optimizing and innovating immunotherapeutic strategies by comprehensively understanding the structure and function of immunosuppressive TME in HCC.
肝细胞癌(HCC)是一种具有高度异质性的恶性肿瘤,其发病率、复发率和转移率都很高。免疫疗法的出现改善了晚期HCC的治疗,但临床实践中仍存在耐药性和免疫相关不良事件等问题。HCC的免疫抑制肿瘤微环境(TME)限制了免疫疗法的疗效,并且对HCC的进展和转移至关重要。因此,有必要阐明免疫抑制TME背后的机制,以开发和应用免疫疗法。本综述系统地总结了HCC的发病机制、高度异质性TME的形成,以及免疫抑制TME加速HCC进展和转移的机制。我们还综述了HCC免疫疗法的现状,并进一步讨论了针对免疫抑制TME的现有挑战和潜在治疗策略。我们希望通过全面了解HCC中免疫抑制TME的结构和功能,激发优化和创新免疫治疗策略。